Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $1,037,704.40 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 18,334 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $56.60, for a total transaction of $1,037,704.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ryan J. Watts also recently made the following trade(s):

  • On Thursday, February 11th, Ryan J. Watts sold 9,473 shares of Denali Therapeutics stock. The stock was sold at an average price of $70.30, for a total transaction of $665,951.90.

Shares of Denali Therapeutics stock opened at $52.43 on Thursday. The stock has a market cap of $6.34 billion, a price-to-earnings ratio of -23.72 and a beta of 2.00. The firm’s 50-day moving average is $61.08 and its two-hundred day moving average is $62.42. Denali Therapeutics Inc. has a 1 year low of $17.74 and a 1 year high of $93.94.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 25th. The company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $2.00. The firm had revenue of $316.82 million for the quarter, compared to the consensus estimate of $87.98 million. Denali Therapeutics had a negative net margin of 968.59% and a negative return on equity of 39.19%. Research analysts predict that Denali Therapeutics Inc. will post -2.2 earnings per share for the current year.

Several large investors have recently made changes to their positions in DNLI. Crestline Management LP raised its position in shares of Denali Therapeutics by 59.5% in the 4th quarter. Crestline Management LP now owns 19,462,500 shares of the company’s stock worth $339,037,000 after acquiring an additional 7,260,866 shares in the last quarter. Baillie Gifford & Co. grew its stake in Denali Therapeutics by 12.6% in the fourth quarter. Baillie Gifford & Co. now owns 12,190,256 shares of the company’s stock valued at $1,021,056,000 after purchasing an additional 1,363,078 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Denali Therapeutics by 48.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,464,826 shares of the company’s stock worth $541,494,000 after purchasing an additional 2,103,851 shares in the last quarter. BlackRock Inc. raised its holdings in Denali Therapeutics by 4.8% in the fourth quarter. BlackRock Inc. now owns 6,376,078 shares of the company’s stock worth $534,062,000 after purchasing an additional 290,761 shares in the last quarter. Finally, Credit Suisse AG lifted its position in shares of Denali Therapeutics by 1,626.2% during the fourth quarter. Credit Suisse AG now owns 1,402,750 shares of the company’s stock valued at $117,494,000 after buying an additional 1,321,486 shares during the last quarter. Institutional investors and hedge funds own 68.15% of the company’s stock.

A number of research analysts have recently commented on the company. TheStreet raised Denali Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 26th. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research report on Friday, January 8th. They issued a “positive” rating on the stock. Zacks Investment Research upgraded Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 target price for the company in a research report on Friday, February 19th. Morgan Stanley upped their price target on shares of Denali Therapeutics from $75.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, December 16th. Finally, Cantor Fitzgerald upgraded shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating and set a $105.00 price objective for the company in a report on Wednesday, February 10th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $74.63.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

Further Reading: Pattern Day Trader

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.